Bupivacaine

Generic Name: Bupivacaine

Brand Names: Exparel, Kenalog, Marbeta, Marcaine, Marcaine With Epinephrine, Marvona Suik, P-Care M, P-Care MG, P-care, Posimir, Readysharp Anesthetics Plus Ketorolac, Readysharp-A, Readysharp-p40, Readysharp-p80, Sensorcaine, Sensorcaine With Epinephrine, Vivacaine, Xaracoll, Exparel liposomal

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₈N_₂O

CAS Number: 38396-39-3

Unique Ingredient Identifier: Y8335394RO

Background: Bupivacaine is a widely used local anesthetic agent.

Indication: As an implant, bupivacaine is indicated in adults for placement into the surgical site to produce postsurgical analgesia for up to 24 hours following open inguinal hernia repair.

Bupivacaine, in liposome suspension, is indicated in patients aged 6 years and older for single-dose infiltration to produce postsurgical local analgesia. In adults, it is also indicated as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.

Bupivacaine, in combination with meloxicam, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Bupivacaine, alone or in combination with epinephrine, is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations are recommended for each type of block indicated to produce local or regional anesthesia or analgesia. Finally, its use is not indicated in all blocks given clinically significant risks associated with use.

Associated Conditions: Acute Gouty Arthritis, Adrenocortical Insufficiency, Alopecia Areata (AA), Ankylosing Spondylitis (AS), Berylliosis, Bullous dermatitis herpetiformis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatomyositis (DM), Discoid Lupus Erythematosus (DLE), Edema of the cerebrum, Epicondylitis, Hemolytic Anemia, Hypercalcemia caused by Cancer, Keloids Scars, Leukemias, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Ocular Inflammation, Ophthalmia, Sympathetic, Osteoarthritis (OA), Pain, Labor, Polymyositis, Postoperative pain, Psoriatic Arthritis, Psoriatic plaque, Pure Red Cell Aplasia, Regional Enteritis, Rheumatoid Arthritis, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Acute Bursitis, Acute Idiopathic Nephrotic Syndrome, Acute Lupus Erythematosus, Acute Multiple sclerosis, Acute Rheumatic heart disease, unspecified, Acute nonspecific tenosynovitis, Cystic tumors of aponeurosis, Cystic tumors of tendon, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Inflammatory lesions of granuloma annulare, Inflammatory lesions of lichen planus, Inflammatory lesions of lichen simplex, Non-suppurative Thyroiditis, Permphigus, Severe Allergic Reactions

Associated Therapies: General Anesthesia, Local Anaesthesia therapy, Regional nerve block therapy

Clinical Trials

Efficacy of Exparel (TM) on Post-operative Pain After Laparoscopic Gastric Bypass Using Circular EEA Stapler

Phase 4

Completed

Conditions: Post-operative Pain Management

Interventions: Drug: Bupivacaine
Drug: Exparel

First Posted Date: 2017-06-14

Last Posted Date: 2022-06-21

Lead Sponsor: Matthew Kroh

Target Recruit Count: 102

Registration Number: NCT03187379

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

Optimal Injection Site for Serratus Anterior Plane Block in Reconstructive Breast Surgery

Phase 3

Withdrawn

Conditions: Pain, Postoperative

Interventions: Drug: Bupivacaine
Drug: Dexamethasone

First Posted Date: 2017-06-12

Last Posted Date: 2018-05-31

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT03183596

Locations: 🇺🇸
UAB Department of Anesthesiology and Perioperative Medicine, Birmingham, Alabama, United States

Supine Versus Left Lateral Tilted Position During Cesarean Delivery

Phase 4

Conditions: Cesarean Section Complications

Interventions: Other: supine position
Other: left lateral tilted position
Drug: Bupivacaine

First Posted Date: 2017-06-09

Last Posted Date: 2018-07-09

Lead Sponsor: Cairo University

Target Recruit Count: 450

Registration Number: NCT03182114

Locations: 🇪🇬
Cairo University, Cairo, Egypt

Norepinephrine Infusion Different Doses in Cesarean Delivery

Phase 4

Completed

Conditions: Cesarean Section Complications

Interventions: Drug: norepinephrine infusion (0.025 mcg/Kg/min)
Drug: norepinephrine infusion (0.050 mcg/Kg/min)
Drug: norepinephrine infusion (0.075 mcg/Kg/min)
Drug: Bupivacaine

First Posted Date: 2017-06-09

Last Posted Date: 2018-08-24

Lead Sponsor: Cairo University

Target Recruit Count: 284

Registration Number: NCT03182088

Locations: 🇪🇬
Cairo University, Cairo, Egypt

Efficiency of Thoracolumbar Interfascial Plane Block in Lumbar Disk Surgery

Phase 4

Conditions: Postoperative Pain

Interventions: Drug: Bupivacaine

First Posted Date: 2017-06-08

Last Posted Date: 2017-11-13

Lead Sponsor: Erzurum Palandöken State Hospital

Target Recruit Count: 50

Registration Number: NCT03180099

Locations: 🇹🇷
Erkan Cem ÇELİK, Erzurum, Turkey

Scalp Block: Hemodynamic Stability and Patient Comfort In Craniotomy Patients

Phase 1

Withdrawn

Conditions: Tumor, Brain
Anesthesia, Local

Interventions: Drug: Lidocaine
Drug: Sodium chloride
Drug: Bupivacaine

First Posted Date: 2017-06-06

Last Posted Date: 2020-10-22

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT03177252

Peripheral Nerve Blocks for Major Lower Extremity Amputations

Phase 4

Terminated

Conditions: Postoperative Pain

Interventions: Drug: Saline Solution
Drug: Bupivacaine

First Posted Date: 2017-06-05

Last Posted Date: 2023-06-12

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 42

Registration Number: NCT03174782

Locations: 🇺🇸
Community Regional Medical Center, Fresno, California, United States

Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections

Phase 4

Completed

Conditions: C-Section
Pain Management

Interventions: Drug: Exparel + Bupivacaine
Drug: Bupivacaine

First Posted Date: 2017-06-05

Last Posted Date: 2021-01-06

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 186

Registration Number: NCT03176459

Locations: 🇺🇸
Loma Linda University, Loma Linda, California, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 9 locations